| INTRODUCTION
Human immunodeficiency virus (HIV), transmitted through sexual and percutaneous routes, is the causative agent for AIDS, the most devastating disaster in the world. 1 In recent years, the patterns of transmission about the HIV/AIDS incidence have shifted markedly in worldwide. It is reported that nearly 501 000 people were living with HIV/AIDS in China at the end of 2014, 2 while the infection increased in MSM (men who have sex with men) and fell in IDU (intravenous drug use) generally. [3] [4] [5] Cohort studies suggest that the rate of HIV transmission in recent infections is much higher compared to established infections. [6] [7] [8] Over the past decades, great progress has been made in serologic assays for detection of HIV infection, especially to permit acute HIV infection (AHI) detection. 9 AHI, only diagnosed through nucleic acids, viral antigens or both, is crucial for antiretroviral therapy and prevention of transmission. 10 The fourth-generation assays, which allow simultaneous detection of p24 antigen and HIV-1/2 antibodies, are gradually replacing thirdgeneration assays to shorten the diagnostic window prior to seroconversion. In current diagnostic algorithms, the fourth-generation assays are implemented worldwide as an initial test. Nevertheless, multiple studies indicated that test performance may vary significantly in different demographic factors and geographic regions. 11, 12 As understanding the performance of fourth-generation assay in local region is pivotal to interpret the test result correctly, in the present study, we set out to analyze the Elecsys ® HIV combi PT assay in Shaocong Liang and Guihua Deng contributed equally our hospital with a situation of low HIV prevalence. The Elecsys ® HIV combi PT assay had been used in our laboratory for more than 2 years, some problems emerged during the testing processes. We retrospectively analyzed the results in these 2 years like false-positive, appropriate cutoff value for diagnosis, and so on. This study will help us to understand more about diagnosis of HIV.
| MATERIALS AND METHODS

| Specimens and assays
Serum samples submitted for HIV screening were processed at Zhujiang Hospital during this study, between June 2013 and October 2015. Venous blood was collected in no additive vacuum tubes for serum (Guangzhou Improve Medical Instruments Co., Ltd.). Samples were centrifuged for 10 minute at 1760 × g (room temperature) before test.
The Elecsys ® HIV combi PT assay, which was developed to be more sensitive and specificity compare to the previous assay, 13 was performed on a Cobas e601 analyzer (Roch Diagnostics GmbH, Mannheim, Germany) for screening HIV infection. Figure 1 demonstrates the procedure of HIV testing in this study.
| Routine test procedure
Results were expressed as in form of s/co ratios. According to the man- 
| HIV confirmatory tests procedure
In CDC laboratory, collected specimens were further tested by thirdgeneration assay (ELISA; Livzon Diagnostics Inc., Zhuhai, China) and 
| Additional Tests
Specimens with initially reactive results were collected and stored at 
| Data collection and analyses
Most of the data were obtained from the clinical laboratory information system. HIV confirmatory test results were provided by CDC via paper-based reports. Statistical analyses were performed using GraphPad prism 5.0 (GraphPad Software, Inc, La Jolla, CA, USA). We excluded the data when the test was repeated in an individual.
| RESULTS
Between June 2013 and October 2015, a total of 85 043 specimens were tested using the Elecsys ® HIV combi PT assay. From Figure 1 , of the 85 043 specimens, 84 776 (99.69%) were non-reactive with the s/ co<0.9. Of the 85 043 specimens, 267 samples were either borderline or initially reactive were retested using the fourth-generation ELISA assays. Finally, 83 specimens with initially reactive were determined to be HIV infected by CDC, while all the borderline specimens were negative throughout the procedure. One case with initially reactive was not performed on entire procedure for unknown reason. The HIV prevalence in this study is slightly higher than previous report, which was studied in general Chinese population in 2011, 4 but it remains low at 0.098% (83/85043). value for the fourth-generation assay was within the confidence bounds reported by specification for unselected samples of daily. The positive predictive value (PPV) on male was higher than female significantly, while the false-positive rate (FPR) was 0.15% and 0.18%.
In the initially reactive cases, 80.22% (73/91) female was determined to be false-positive, which is nearly twofold to the male (45.52%, 66/145).
The median (interquartile range) and distribution of s/co ratios are illustrated in Figure 2 , which shows that the gap between false- (Table 3) .
We also selected 20 specimens with s/co >1.00 randomly to perform the Elecsys ® HIV p24 Ag assay on E601 (Table 4) Table 5 . 
| DISCUSSION
In this study, over 80 000 specimens were performed by the Elecsys® HIV combi PT assay. Excellent specificity and rare FPR (less than two in a thousand) were shown. Yet, the PPV values varied apparently in genders. The PPV on male was 50.75%, while it was 17.05% on female. Furthermore, we find that high s/co ratio was predictive of Various reasons attribute to the false-positive results, such as contamination, impure recombinant HIV antigens used in HIV kits 14 or recent influenza vaccination, 15 infections, 14 pregnancy, 16 transplantation, autoimmune diseases, and even fibrin microclots. 17 In this study, we retested 20 initially reactive specimens by a p24 Ag assay to find if the components equipped on fourth-generation assays to detect the p24 Ag will lead to the false-positive results. Nevertheless, the relationship was not found from Table 4 .
In fact, investigators consider that nonspecific polyclonal B-cell activation which aroused by certain infections will produce uncontrolled antibodies. 14, 18 Cross-reaction by broad-spectrum antibodies during the course of immunoreaction result in false-positive results.
It is consistent with our findings that 19.4% (27/139) false-positive in this study are diagnosed for infection. The case with confirmatory test not performed was excluded.
T In addition, pregnancy, another common cause in charge falsepositive, has been described in several studies. It accounted for 8.6%
of the false-positive individuals which may be the main cause to the lower PPV about female in this study. However, the mechanisms are still unknown, and alloimmunization may participate in it.
We also find that malignancy takes up 14.4% (20/139) of the diagnoses in false-positive individuals. Relative research on this topic is rare. 19 The relationship between malignancy and false-positive is not clear. We hypothesis that patients with cancer are not only prone to infections, but also have a state of immune system disorders.
Furthermore, the components of tumor cell membranes, cytosol, or excreted products from the tumor issues may lead to the polyclonal B-cell activation. Indeed, studies have shown that the immune system produces non-organ specific antibodies, which may be cross-reactivity with immune reagents, at the initial stage of immune response. 20 Besides, high fibrinogen levels and hypercoagulation, correlated with distant metastasis, 21, 22 are common in patients with malignancy. The fibrin microclots, difficult to be removed by centrifugal force, formed easily in the specimens from these patients, especially with inadequate mixing. It may interfere with the assay to a false-positive result. 
| CONCLUSION
In this research, the Elecsys ® HIV combi PT shows excellent specificity. However, optimal cutoff value is needed to be set to reduce the false-positive rate and predict the final status of HIV infection reliably. 
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